Tukysa Approved as Combo Therapy for Metastatic HER2-positive Breast Cancer in Switzerland

Tukysa Approved as Combo Therapy for Metastatic HER2-positive Breast Cancer in Switzerland
The Swiss Agency for Therapeutic Products (Swissmedic) has approved Seattle GeneticsTukysa, in combination with trastuzumab and Xeloda (capecitabine), for the treatment of patients with metastatic HER2-positive breast cancer. Tukysa is now approved for individuals who have been treated previously with at least two other anti-HER2 therapies, examples of which include Kadcycla (ado-trastuzumab emtansine)Perjeta (pertuzumab), and trastuzumab (sold under the brand name Herceptin, among others). Swissmedic reviewed the Tukysa application as part of Project Orbis. This initiative, from the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence, gives a framework for simultaneous submission and review of cancer-treating medications among multiple international regulatory agencies. In addition to the U
Subscribe or to access all post and page content.